Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 317 5050

Website: legendbiotech.com

Address:

2101 Cottontail Lane, Somerset, United States

topstockalerts May. 12 at 9:36 PM

$LEGN this chart has gone from boring to very interesting.

0 · Reply

kiwiSurfer May. 12 at 9:02 PM

$LEGN On the Cusp of $32-$35 🔜

0 · Reply

RunnerSignals May. 12 at 8:29 PM

Top Stock Market Warriors $DGXX $MRAM $AEVA $LEGN $WOLF Reversing Hard From Red to Green

0 · Reply

Buyout_Imminent May. 12 at 7:35 PM

$LEGN if you don't think they paint the charts..

0 · Reply

DiamondHandsBTW May. 12 at 7:32 PM

$LEGN I believe BO is around the corner

0 · Reply

z_guy May. 12 at 7:20 PM

$LEGN we’ve got our money back

0 · Reply

Greenspam May. 12 at 6:26 PM

$LEGN Something is brewing and coming....

0 · Reply

JFDI May. 12 at 6:25 PM

The $LEGN!

0 · Reply

Greenspam May. 12 at 6:19 PM

$LEGN

0 · Reply

Annaba514 May. 12 at 4:24 PM

$LEGN I just got it at 26.5$/sh.. I am in the first time

0 · Reply

Legend Biotech reports Q1 EPS (3c), consensus (17c)

May 12, 2026, 8:00 AM EDT - 1 day ago

Legend Biotech Earnings Call Transcript: Q1 2026

May 12, 2026, 7:00 AM EDT - 1 day ago

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

May 4, 2026, 8:00 AM EDT - 9 days ago

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Apr 28, 2026, 8:00 AM EDT - 15 days ago

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

2026-03-11T12:52:50.000Z - 2 months ago

Legend Biotech price target lowered to $49 from $50 at Morgan Stanley

2026-03-11T12:39:24.000Z - 2 months ago

Legend Biotech price target lowered to $62 from $66 at RBC Capital

Mar 10, 2026, 8:00 AM EDT - 2 months ago

Legend Biotech Earnings Call Transcript: Q4 2025

2026-03-10T11:06:40.000Z - 2 months ago

Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year

2026-03-10T11:05:54.000Z - 2 months ago

Legend Biotech sees cash runway beyond 2026

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

2026-03-09T13:06:19.000Z - 2 months ago

Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank

Feb 24, 2026, 8:00 AM EST - 2 months ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

2026-02-23T15:07:34.000Z - 2 months ago

Legend Biotech rises 16.6%

2026-02-12T11:46:34.000Z - 3 months ago

Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn

2026-02-04T10:50:59.000Z - 3 months ago

Legend Biotech price target lowered to $80 from $90 at Barclays

2026-01-22T11:10:15.000Z - 3 months ago

Legend Biotech price target lowered to $50 from $60 at H.C. Wainwright

2026-01-22T02:55:09.000Z - 3 months ago

Legend Biotech downgraded to Hold from Buy at TD Cowen

2026-01-21T17:06:33.000Z - 3 months ago

Legend Biotech falls -12.7%

2026-01-21T15:06:14.000Z - 3 months ago

Legend Biotech falls -10.5%

2026-01-20T16:25:14.000Z - 4 months ago

FDA draft guidance favorable for Legend Biotech, says RBC Capital

Jan 14, 2026, 12:00 PM EST - 4 months ago

Legend Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T13:25:13.000Z - 4 months ago

Legend Biotech sees cash runway beyond 2026

2026-01-07T13:35:29.000Z - 4 months ago

Legend Biotech initiated with an Outperform at Oppenheimer

2025-12-17T12:55:19.000Z - 5 months ago

Legend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald

2025-12-15T21:25:11.000Z - 5 months ago

Legend Biotech management to meet with Cantor Fitzgerald

2025-12-12T13:18:08.000Z - 5 months ago

Legend Biotech price target lowered to $50 from $83 at Morgan Stanley

Dec 9, 2025, 3:31 PM EST - 5 months ago

Cancer Study Buoys These Small Biotechs

ACLX TERN

2025-12-09T17:30:23.000Z - 5 months ago

Carvykti strength holds, Legend Biotech weakness overdone, says RBC Capital

JNJ

Dec 6, 2025, 2:00 PM EST - 5 months ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Nov 13, 2025, 12:08 PM EST - 6 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Nov 12, 2025, 8:00 AM EST - 6 months ago

Legend Biotech Earnings Call Transcript: Q3 2025

Nov 3, 2025, 11:05 AM EST - 6 months ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 7 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Oct 10, 2025, 6:36 PM EDT - 7 months ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

JNJ

Sep 9, 2025, 4:05 PM EDT - 8 months ago

Legend Biotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 18, 2025, 8:00 AM EDT - 9 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Legend Biotech Earnings Call Transcript: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 9 months ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM VRNA

Jun 3, 2025, 10:45 AM EDT - 1 year ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

May 22, 2025, 5:15 PM EDT - 1 year ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 19, 2024, 8:01 AM EST - 1 year ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 1 year ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 8, 2024, 11:00 PM EST - 1 year ago

Legend Biotech Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 1 year ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 27, 2024, 4:35 PM EDT - 1 year ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 1 year ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 4, 2024, 2:35 PM EDT - 1 year ago

Legend Biotech Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Jun 6, 2024, 10:30 AM EDT - 2 years ago

Legend Biotech Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 4:00 PM EDT - 2 years ago

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

May 29, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 2 years ago

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 13, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings Call Transcript: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

$CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma$

Apr 22, 2024, 1:05 PM EDT - 2 years ago

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

Apr 5, 2024, 11:30 PM EDT - 2 years ago

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

topstockalerts May. 12 at 9:36 PM

$LEGN this chart has gone from boring to very interesting.

0 · Reply

kiwiSurfer May. 12 at 9:02 PM

$LEGN On the Cusp of $32-$35 🔜

0 · Reply

RunnerSignals May. 12 at 8:29 PM

Top Stock Market Warriors $DGXX $MRAM $AEVA $LEGN $WOLF Reversing Hard From Red to Green

0 · Reply

Buyout_Imminent May. 12 at 7:35 PM

$LEGN if you don't think they paint the charts..

0 · Reply

DiamondHandsBTW May. 12 at 7:32 PM

$LEGN I believe BO is around the corner

0 · Reply

z_guy May. 12 at 7:20 PM

$LEGN we’ve got our money back

0 · Reply

Greenspam May. 12 at 6:26 PM

$LEGN Something is brewing and coming....

0 · Reply

JFDI May. 12 at 6:25 PM

The $LEGN!

0 · Reply

Greenspam May. 12 at 6:19 PM

$LEGN

0 · Reply

Annaba514 May. 12 at 4:24 PM

$LEGN I just got it at 26.5$/sh.. I am in the first time

0 · Reply

kiwiSurfer May. 12 at 4:03 PM

$LEGN lets Go!

0 · Reply

Buyout_Imminent May. 12 at 3:22 PM

$LEGN Buyout offer and suitcase of cash are in after the stellar call by the team. Congratulations everyone!

1 · Reply

GeniusLoci May. 12 at 3:14 PM

$LEGN

0 · Reply

kiwiSurfer May. 12 at 3:00 PM

$LEGN Strategic Context: • Diversification: Legend is currently seen as a "one-drug company" due to Carvykti. Strong LB1908 results are essential for the stock to achieve the $57+ target price many analysts have set for 2026, as it proves the platform's success in solid tumors. Breakthrough Designation?

0 · Reply

Bondra May. 12 at 2:37 PM

$LEGN BANG

0 · Reply

forprofit12 May. 12 at 2:29 PM

$LEGN

0 · Reply

BiodegradableBurger May. 12 at 1:50 PM

$LEGN Won’t be surprised if we go green and even claw back some of the loses from Yesterday. The drop is just absurd.

0 · Reply

kiwiSurfer May. 12 at 1:45 PM

$LEGN this is a Big Deal: PhII readout: Claudin 18.2 is a "goldilocks" target. It is highly expressed in gastric, gastroesophageal junction, and pancreatic adenocarcinomas, but its expression in healthy tissue is largely restricted to the stomach lining. This allows the CAR-T cells to hunt cancer cells while minimizing "off-target" damage to vital organs.

0 · Reply

z_guy May. 12 at 1:09 PM

$LEGN it seems there’s disconnect between S/P and progress in this company … “Compared to the first quarter of 2025, CARVYKTI® net trade sales increased 62% in the first quarter of 2026 to approximately $597 million, with U.S. net trade sales growth of 36% and ex-U.S. net trade sales growth of 222%. Launched CARVYKTI® in Italy, Poland, the Czech Republic, and Australia, bringing availability to more than 300 global sites and 18 global markets.”

0 · Reply

MarketBeat May. 12 at 1:09 PM

https://marketbeat.com/a/8650492/ $LEGN Legend Biotech Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 1:00 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-legend-biotech-co-stock/ $LEGN Legend Biotech Earnings Transcript

0 · Reply

mulc May. 12 at 12:52 PM

$LEGN Seems like slight miss.

0 · Reply

Market Cap	4.73B
Revenue (ttm)	1.03B
Net Income (ttm)	-296.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	90.71
Profit Margin	-28.85%
Debt to Equity Ratio	0.32

Volume	5,050,500
Avg Vol	2,084,082
Day's Range	N/A - N/A
Shares Out	184.96M
Stochastic %K	73%
Beta	0.29
Analysts	Strong Sell
Price Target	$60.65